Nimesulide-induced fatal acute liver failure in an elderly woman with metastatic biliary adenocarcinoma
a case report
Keywords:
Anti-inflammatory agents, non-steroidal, Liver failure, acute, Drug-induced liver injury, Cholestasis, Drug toxicityAbstract
CONTEXT: Nimesulide is a selective inhibitor of the enzyme cyclooxygenase 2. Although considered to be a safe drug, cases of acute hepatitis and fulminant liver failure have been reported in Europe, the United States and South America, especially among elderly female patients. Until now, there had not been any reports in the literature relating to Brazilian subjects. CASE REPORT: An 81-year old female who had been using nimesulide therapy for six days presented hematemesis and epistaxis two days before hospitalization. Clinical examination showed an extensive coagulation disorder, diffuse hematomas, hypotension and tachypnea. Laboratory tests revealed abnor-malities in coagulation tests; leukocytosis; reduced platelet, hemoglobin and red blood cell counts; and elevated direct bilirubin, serum aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase and renal function biomarkers. Hepatitis B and C tests were not reactive. Carcino-embryonic antigen (CEA), CA-19-9 and CA-125 levels were increased by, respectively, 1,000, 10,000 and 13 fold, whereas the alpha-fetoprotein level was normal, thus indicating a malignant tumor in the bile duct that did not originate from the liver. Thirty-six hours after hospitalization, the patient’s condition worsened, leading to death. The necropsy findings included acute hepatitis with hepatocellular collapse, as well as metastasis of a carcinoma, probably from the bile duct. CONCLUSION: Despite the carcinoma presented by the patient, nimesulide use may have contributed towards the fatal acute liver failure. Until this issue has been clarified, caution is required in prescribing nimesulide for liver disease patients.
Downloads
References
Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet. 1998;35(4):247-74.
Merlani G, Fox M, Oehen HP, et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol. 2001;57(4):321-6.
Walker SL, Kennedy F, Niamh N, McCormick PA. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf. 2008;17(11):1108-12.
Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010;16(45):5651-61.
Tan HH, Ong WM, Lai SH, Chow WC. Nimesulide-induced hepatotoxicity and fatal hepatic failure. Singapore Med J. 2007;48(6):582-5.
Schattner A, Sokolovskaya N, Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide. J Inter Med. 2000;247(1):153-5.
Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 2002;25(9):633-48.
Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327(7405):18-22.
Grignola Rial JC, Arias Gorga LI, Rondan Olivera M, Solá Schnir L, Bagnulo Saccomandi HL. Hepatotoxicidad asociada a la nimesulida: revisión de 5 casos [Hepatotoxicity associated to Nimesulida: revision of 5 cases]. Arch Med Interna (Montevideo). 1998;20(1):13-8.
Van Steenbergen W, Peeters P, De Bondt J, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol. 1998;29(1):135-41.
Moreno AJ, Oliveira PJ, Nova CD, et al. Unaltered hepatic oxidative phosphorylation and mitochondrial permeability transition in wistar rats treated with nimesulide: Relevance for nimesulide toxicity characterization. J Biochem Mol Toxicol. 2007;21(2):53-61.
Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010;19(7):708-14.
Licata A, Calvaruso V, Cappello M, Craxì A, Almasio PL. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis. 2010;42(2):143-8.
Stadlmann S, Zoller H, Vogel W, Offner FA. COX-2 inhibitor (nimesulide) induced acute liver failure. Virchows Arch. 2002;440(5):553-5.
Sbeit W, Krivoy N, Shiller M, et al. Nimesulide-induced acute hepatitis. Ann Pharmacother. 2001;35(9):1049-52.
Gallelli L, Ferraro M, Mauro GF, De Fazio S, De Sarro G. Nimesulide-induced hepatotoxicity in a previously healthy woman. Clin Drug Investig. 2005;25(6):421-4.
Singh BK, Tripathi M, Chaudhari BP, Pandey PK, Kakkar P. Natural terpenes prevent mitochondrial dysfunction, oxidative stress and release of apoptotic proteins during nimesulide-hepatotoxicity in rats. PLoS One. 2012;7(4):e34200.
Singh BK, Tripathi M, Pandey PK, Kakkar P. Nimesulide aggravates redox imbalance and calcium dependent mitochondrial permeability transition leading to dysfunction in vitro. Toxicology. 2010;275(1-3):1-9.
Mingatto FE, Rodrigues T, Pigoso AA, et al. The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J Pharmacol Exp Ther. 2002;303(2):601-7.
Monteiro JP, Martins AF, Lúcio M, et al. Nimesulide interaction with membrane model systems: are membrane physical effects involved in nimesulide mitochondrial toxicity? Toxicol In Vitro. 2011;25(6):1215-23.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician. 2004;69(2):299-304.
Dufour MD. Liver disease. In: Burtis CA, Ashwood ER, Bruns DE. Tietz fundamentals of clinical chemistry. 6th ed. Philadelphia: Saunders; 2007. p. 691-712.
Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost. 2001;86(3):828-33.
Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004;124(5):567-76.
Apostolou T, Sotsiou F, Yfanti G, et al. Acute renal failure induced by nimesulide in a patient suffering from temporal arteritis. Nephrol Dial Transplant. 1997;12(7):1493-6.
Dalton WS, Friend SH. Cancer biomarkers--an invitation to the table. Science. 2006;312(5777):1165-8.
Ramírez CP, Suárez MA, Santoyo JL, et al. Actualización del diagnóstico y el tratamiento del cáncer devesícula biliar. Cirugía Española. 2002;71(2):102-11. Available from: http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13026792&pident_usuario=0&pcontactid=&pident_revista=36&ty=12&accion=L&origen=zonadelectura&web=zl.elsevier.es&lan=es&fichero=36v71n02a13026792pdf001.pdf. Accessed in 2014 (Jan 28).
Brockmann J, Emparan C, Hernandez CA, et al. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies. Anticancer Res. 2000;20(6D):4941-7.
Moral A, Magarzo J. Marcadores tumorales serológicos en cirugía hepatobiliopancreática. Cirugía Española. 2004;76(5):276-83. Available from: http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=13067974&pident_usuario=0&pcontactid=&pident_revista=36&ty=154&accion=L&origen=zonadelectura&web=zl.elsevier.es&lan=es&fichero=36v76n05a13067974pdf001.pdf. Accessed in 2014 (Jan 28).
Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5(1):145-59.
Carraro P, Burighel D, De Silvestro G, Gaiotto M, Plebani M. Early prognostic biochemical indicators of fulminant hepatic failure. Int J Clin Lab Res. 1998;28(3):196-9.
Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990;12(6):1420-32.
Schmidt LE, Dalhoff K. Alpha‐fetoprotein is a predictor of outcome in acetaminophen‐induced liver injury. Hepatology. 2005;41(1):26-31.
